Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for B2RQE8

Entry ID Method Resolution Chain Position Source
AF-B2RQE8-F1 Predicted AlphaFoldDB

28 variants for B2RQE8

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3389022102 62 Q>H No EVA
rs3389024827 75 A>V No EVA
rs3399902053 86 S>* No EVA
rs3399597115 89 E>K No EVA
rs3399597153 102 R>H No EVA
rs3399782360 106 Q>K No EVA
rs3399797936 116 L>FEISQGVQLIHH* No EVA
rs3389028392 153 E>D No EVA
rs1133464658 184 A>V No EVA
rs49152858 207 S>T No EVA
rs3389028342 208 T>N No EVA
rs3389004118 307 F>V No EVA
rs3389022140 327 N>I No EVA
rs3389028360 355 Y>* No EVA
rs3389025507 375 G>C No EVA
rs3389019733 448 K>* No EVA
rs3389022501 480 H>R No EVA
rs3389022523 497 N>K No EVA
rs3389011375 500 V>I No EVA
rs3389025453 516 A>V No EVA
rs3389018797 646 W>R No EVA
rs3389028416 647 T>I No EVA
rs3389004045 736 I>K No EVA
rs3389028402 744 K>E No EVA
rs3389022133 746 C>R No EVA
rs47135914 782 V>L No EVA
rs3388998406 797 E>K No EVA
rs239110357 815 P>L No EVA

No associated diseases with B2RQE8

No regional properties for B2RQE8

Type Name Position InterPro Accession
No domain, repeats, and functional sites for B2RQE8

Functions

Description
EC Number
Subcellular Localization
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

No GO annotations of cellular component

Name Definition
No GO annotations for cellular component

1 GO annotations of molecular function

Name Definition
GTPase activator activity Binds to and increases the activity of a GTPase, an enzyme that catalyzes the hydrolysis of GTP.

5 GO annotations of biological process

Name Definition
activation of GTPase activity Any process that initiates the activity of an inactive GTPase through the replacement of GDP by GTP.
negative regulation of Rho protein signal transduction Any process that stops, prevents, or reduces the frequency, rate or extent of Rho protein signal transduction.
negative regulation of systemic arterial blood pressure The process that reduces the force with which blood travels through the systemic arterial circulatory system.
negative regulation of vascular associated smooth muscle contraction Any process that stops, prevents or reduces the frequency, rate or extent of vascular smooth muscle contraction.
signal transduction The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.

9 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q5ZMW5 ARHGAP26 Rho GTPase-activating protein 26 Gallus gallus (Chicken) PR
Q7YQL6 OPHN1 Oligophrenin-1 Pan troglodytes (Chimpanzee) PR
O60890 OPHN1 Oligophrenin-1 Homo sapiens (Human) PR
Q9UNA1 ARHGAP26 Rho GTPase-activating protein 26 Homo sapiens (Human) PR
A6NI28 ARHGAP42 Rho GTPase-activating protein 42 Homo sapiens (Human) PR
Q6ZQ82 Arhgap26 Rho GTPase-activating protein 26 Mus musculus (Mouse) PR
Q99J31 Ophn1 Oligophrenin-1 Mus musculus (Mouse) PR
P0CAX5 Ophn1 Oligophrenin-1 Rattus norvegicus (Rat) PR
B5DFQ4 arhgap26 Rho GTPase-activating protein 26 Xenopus tropicalis (Western clawed frog) (Silurana tropicalis) PR
10 20 30 40 50 60
MGLPTLEFSD SYLDSPDFRE RLQCHEIELE RTNKFIKELL KDGSLLIGAL RNLSMAVQKF
70 80 90 100 110 120
SQSLQDFQFE CIGDAETDDE ISIAQSLKEF ARLLIAVEEE RRRLIQNAND VLIAPLEKFR
130 140 150 160 170 180
KEQIGAAKAD SQIGREHQNF YEASLEYVFK IQEVQEKKKF EFVEPLLSFL QGLFTFYHEG
190 200 210 220 230 240
YELAQEFAPY KQQLQFNLQN TRNNFESTRQ EVERLMQRMK SANQDYRPPS QWTMEGYLYV
250 260 270 280 290 300
QEKRPLGFTW TKHYCTYDKG SKMFTMSVSD VKASGKMNGL VTGSPEMFKL KSCIRRKTDS
310 320 330 340 350 360
IDKRFCFDIE VVERHGIITL QAFSEANRKL WLEAMDGKEP IYTLPAIISK KEEMYLNEAG
370 380 390 400 410 420
FNFVRKCIQA VEMRGITILG LYRIGGVNSK VQKLMNTTFS PKSPPDMDID IELWDNKTIT
430 440 450 460 470 480
SGLKNYLRCL AEPLMTYKLH KDFIIAVKSD DQNYRVEAVH ALVHKLPEKN REMLDILIKH
490 500 510 520 530 540
LLKVSLHSQQ NLMTISNLGV IFGPTLMRAQ EETVAAMMNI KFQNIVVEIL IEHYEKIFHT
550 560 570 580 590 600
APDPNIPLPQ PQSRSGSRRT RAICLSTGSR KPRGRYTPCL AEPDSDSYSS SPDSTPMGSI
610 620 630 640 650 660
ESLSSHSSEQ NSTTKSTACQ PREKSGGIPW ITTPSSSNGQ KSQGLWTTSP ESSSREDATK
670 680 690 700 710 720
TDVESDCQSV ASITIPGNVS PPIDLVKKGP YGLSGLKRSS ASSSLRSISA AEGNKSYSGS
730 740 750 760 770 780
IQSLTSIGSK ESPKAIPNPE LPPKMCRRLR LDTASSNGYQ RPGSVVAAKA QLFENAGSPK
790 800 810 820 830 840
PVSSGRQAQA MYSCKAEHSH ELSFPQGAIF SNVHPSVEPG WLKATYEGRT GLVPENYVVF
L